Amit Rakhit - Jul 14, 2021 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role: President and CMO
Signature: /s/ Danielle Mann for Amit Rakhit by PoA
Stock symbol: OVID
Transactions as of: Jul 14, 2021
Transactions value $: -$61,911
Form type: 4
Date filed: 7/16/2021, 06:21 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OVID	Common Stock	Options Exercise	$64.3K	+34K	+4.68%	$1.89	761K	Jul 14, 2021	Direct
transaction	OVID	Common Stock	Sale	-$126K	-34K	-4.47%	$3.71	727K	Jul 14, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OVID	Stock Option (Right to Buy)	Options Exercise	$0	+34K	+59.71%	$0.00	91K	Jul 14, 2021	Common Stock	34K	$1.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4
F2	25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4

25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.